umu.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Jensen, Steen M
Alternative names
Publications (10 of 53) Show all publications
Blomström-Lundqvist, C., Gizurarson, S., Schwieler, J., Jensen, S. M., Bergfeldt, L., Kennebäck, G., . . . Mörtsell, D. (2019). Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients With Atrial Fibrillation: the CAPTAF Randomized Clinical Trial. Journal of the American Medical Association (JAMA), 321(11), 1059-1068
Open this publication in new window or tab >>Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients With Atrial Fibrillation: the CAPTAF Randomized Clinical Trial
Show others...
2019 (English)In: Journal of the American Medical Association (JAMA), ISSN 0098-7484, E-ISSN 1538-3598, Vol. 321, no 11, p. 1059-1068Article in journal (Refereed) Published
Abstract [en]

Importance: Quality of life is not a standard primary outcome in ablation trials, even though symptoms drive the indication.

Objective: To assess quality of life with catheter ablation vs antiarrhythmic medication at 12 months in patients with atrial fibrillation.

Design, setting, and participants: Randomized clinical trial at 4 university hospitals in Sweden and 1 in Finland of 155 patients aged 30-70 years with more than 6 months of atrial fibrillation and treatment failure with 1 antiarrhythmic drug or beta-blocker, with 4-year follow-up. Study dateswere July 2008-September 2017. Major exclusionswere ejection fraction <35%, left atrial diameter > 60 mm, ventricular pacing dependency, and previous ablation.

Interventions: Pulmonary vein isolation ablation (n= 79) or previously untested antiarrhythmic drugs (n= 76).

Main outcomes and measurement: Primary outcomewas the General Health subscale score (Medical Outcomes Study 36-Item Short-Form Health Survey) at baseline and 12 months, assessed unblinded (range, 0 [worst] to 100 [best]). There were 26 secondary outcomes, including atrial fibrillation burden (% of time) from baseline to 12 months, measured by implantable cardiac monitors. The first 3 months were excluded from rhythm analysis.

Results: Among 155 randomized patients (mean age, 56.1 years; 22.6% women), 97% completed the trial. Of 79 patients randomized to receive ablation, 75 underwent ablation, including 2 who crossed over to medication and 14 who underwent repeated ablation procedures. Of 76 patients randomized to receive antiarrhythmic medication, 74 received it, including 8 who crossed over to ablation and 43 for whom the first drug used failed. General Health score increased from 61.8 to 73.9 points in the ablation group vs 62.7 to 65.4 points in the medication group (between-group difference, 8.9 points; 95% CI, 3.1-14.7; P=.003). Of 26 secondary end points, 5 were analyzed; 2 were null and 2 were statistically significant, including decrease in atrial fibrillation burden (from 24.9% to 5.5% in the ablation group vs 23.3% to 11.5% in the medication group; difference -6.8%[95% CI, -12.9% to -0.7%]; P=.03). Of the Health Survey subscales, 5 of 7 improved significantly. Most common adverse events were urosepsis (5.1%) in the ablation group and atrial tachycardia (3.9%) in the medication group.

Conclusions and relevance: Among patients with symptomatic atrial fibrillation despite use of antiarrhythmic medication, the improvement in quality of life at 12 months was greater for those treated with catheter ablation compared with antiarrhythmic medication. Although the study was limited by absence of blinding, catheter ablation may offer an advantage for quality of life.

Place, publisher, year, edition, pages
Chicago: American Medical Association, 2019
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:umu:diva-157956 (URN)10.1001/jama.2019.0335 (DOI)000461683500014 ()30874754 (PubMedID)
Available from: 2019-04-17 Created: 2019-04-17 Last updated: 2019-04-17Bibliographically approved
Kesek, M., Lindmark, D., Rashid, A. & Jensen, S. M. (2019). Increased risk of late pacemaker implantation after ablation for atrioventricular nodal reentry tachycardia: A 10-year follow-up of a nationwide cohort. Heart Rhythm, 16(8), 1182-1188
Open this publication in new window or tab >>Increased risk of late pacemaker implantation after ablation for atrioventricular nodal reentry tachycardia: A 10-year follow-up of a nationwide cohort
2019 (English)In: Heart Rhythm, ISSN 1547-5271, E-ISSN 1556-3871, Vol. 16, no 8, p. 1182-1188Article in journal (Refereed) Published
Abstract [en]

Background: Catheter ablation of the slow pathway is the standard treatment of atrioventricular nodal reentry tachycardia (AVNRT) with a well described low risk of periprocedural atrioventricular block. Less is known about the risk of pacemaker implantation late after ablation.

Objective: We aimed to quantify the risk of late pacemaker implantation in a countrywide cohort undergoing first-time ablation for AVNRT.

Methods: All patients undergoing first-time ablation for AVNRT in Sweden from 2004 to 2014 were identified from the Swedish catheter ablation registry and matched against the Swedish Pacemaker and ICD registry. The cohort was compared to patients ablated for an accessory pathway (AP) and to matched controls.

Results: During follow-up of 2039 days, pacemaker was implanted later than 30 days after ablation in 96 of 6842 patients with AVNRT (1.4%), 29 of 4065 patients with AP (0.7%) (P = .001), and 124 of 33,270 controls (0.4%) (P < .00001). A periprocedural pacemaker (≤30 days postablation) was implanted in 32 of 6877 patients with AVNRT (0.5%) and 9 of 4079 patients with AP (0.2%) (P = .05). With cryoablation, 5 patients needed periprocedural pacemaker implantation. Pacemakers were implanted before ablation in 88 of 6977 patients with AVNRT (1.3%) and 11 of 4100 patients with AP (0.3%); the prevalence of pacemaker implants in controls was 124 of 33,270 (0.4%) (P < .00001 for both comparisons).

Conclusion: The risk of late pacemaker implantation after AVNRT ablation was low but 3 times higher than that in the control population and 3 times higher than the risk of periprocedural pacemaker implantation. Similar results were observed with cryoablation and radiofrequency ablation. Ablation may not be the cause of increased late pacemaker implantation risk.

Place, publisher, year, edition, pages
Elsevier, 2019
Keywords
Ablation, Atrioventricular nodal reentry tachycardia, Cryoablation, Pacemaker, Radiofrequency ablation
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:umu:diva-161980 (URN)10.1016/j.hrthm.2019.02.032 (DOI)000477570700015 ()30826422 (PubMedID)2-s2.0-85068826043 (Scopus ID)
Available from: 2019-08-14 Created: 2019-08-14 Last updated: 2019-08-20Bibliographically approved
Bagge, L., Probst, J., Jensen, S. M., Blomström, P., Thelin, S., Holmgren, A. & Blomström-Lundqvist, C. (2018). Quality of life is not improved aftermitral valve surgery combined with epicardial left atrial cryoablation as compared with mitral valve surgery alone: a substudy of the double blind randomized SWEDish Multicentre Atrial Fibrillation study (SWEDMAF). Europace, 20, F343-F350
Open this publication in new window or tab >>Quality of life is not improved aftermitral valve surgery combined with epicardial left atrial cryoablation as compared with mitral valve surgery alone: a substudy of the double blind randomized SWEDish Multicentre Atrial Fibrillation study (SWEDMAF)
Show others...
2018 (English)In: Europace, ISSN 1099-5129, E-ISSN 1532-2092, Vol. 20, p. F343-F350Article in journal (Refereed) Published
Abstract [en]

Aims: Concomitant surgical ablation of atrial fibrillation (AF) in patients undergoing mitral valve surgery (MVS) has almost become routine despite lack of convincing information about improved quality-of-life (QOL) and clinical benefit. Quality-of-life was therefore assessed after MVS with or without epicardial left atrial cryoablation. Methods and results: Sixty-five patients with permanent AF randomized to MVS with or without left atrial cryoablation, in the doubleblinded multicentre SWEDMAF trial, replied to the Short Form 36 QOL survey at 6 and 12 months follow-up. The QOL scores at 12month follow-up did not differ significantly between patients undergoing MVS combined with cryoablation vs. those undergoing MVS alone regarding Physical Component Summary mean 42.8 (95% confidence interval 38.3-47.3) vs. mean 44.0 (40.1-47.7), P =0.700 or Mental Component Summary mean 53.1 (49.7-56.4) vs. mean 48.4 (44.6-52.2), P=0.075. All patients, irrespective of allocated procedure, reached the same QOL after surgery as an age-matched Swedish general population. The Physical Component Summary in patients with sinus rhythm did also not differ from those in AF at 12months; mean 45.4 (42.0-48.7) vs. mean 40.5 (35.5-45.6), P=0.096) nor was there a difference in Mental Component Summary; mean 51.0 (48.0-54.1) vs. mean 49.6 (44.6-54.5), P=0.581). Conclusion: Left atrial cryoablation added to MVS does not improve health-related QOL in patients with permanent AF, a finding that raises concerns regarding recommendations made for this combined procedure.

Place, publisher, year, edition, pages
Oxford University Press, 2018
Keywords
Quality-of-life, Ablation, Atrial fibrillation, Mitral valve surgery, Concomitant surgical ablation
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:umu:diva-155246 (URN)10.1093/europace/eux253 (DOI)000454047100014 ()29016835 (PubMedID)
Note

Special Issue: 3

Available from: 2019-01-14 Created: 2019-01-14 Last updated: 2019-05-20Bibliographically approved
Höglund, N., Sahlin, C., Kesek, M., Jensen, S. M. & Franklin, K. A. (2017). Cardioversion of atrial fibrillation does not affect obstructive sleep apnea. Upsala Journal of Medical Sciences, 122(2), 114-118
Open this publication in new window or tab >>Cardioversion of atrial fibrillation does not affect obstructive sleep apnea
Show others...
2017 (English)In: Upsala Journal of Medical Sciences, ISSN 0300-9734, E-ISSN 2000-1967, Vol. 122, no 2, p. 114-118Article in journal (Refereed) Published
Abstract [en]

Background: Sleep apnea is common in patients with atrial fibrillation, but the effect of the cardioversion of atrial fibrillation to sinus rhythm on central and obstructive apneas is mainly unknown. The primary aim of the study was to analyze the association between cardioversion of atrial fibrillation and sleep apneas, to investigate whether obstructive or central sleep apneas are reduced following cardioversion. A secondary objective was to study the effect on sleep quality. Methods: Twenty-three patients with atrial fibrillation were investigated using overnight polysomnography, including esophagus pressure monitoring and ECG, before and after the cardioversion of persistent atrial fibrillation. Results: Obstructive sleep apnea occurred in 17/23 patients (74%), and central sleep apnea in 6/23 patients (26%). Five patients had both obstructive and central sleep apnea. Sinus rhythm at follow-up was achieved in 16 patients. The obstructive apnea-hypopnea index, central apnea-hypopnea index, and the number of patients with obstructive or central sleep apnea did not differ before and after restoration of sinus rhythm. Sleep time, sleep efficiency, time in different sleep stages, and subjective daytime sleepiness were normal and unaffected by cardioversion. Conclusions: Both obstructive and central sleep apneas are highly prevalent in patients with persistent atrial fibrillation. Obstructive sleep apneas are unaffected by the cardioversion of atrial fibrillation to sinus rhythm. The sleep pattern is normal and unaffected by cardioversion in patients with atrial fibrillation. Clinical Trial Registration: Trial number NCT00429884.

Place, publisher, year, edition, pages
Taylor & Francis, 2017
Keywords
Atrial fibrillation, cardioversion, polysomnography, sleep apnea
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:umu:diva-135990 (URN)10.1080/03009734.2017.1291545 (DOI)000401756500007 ()28291376 (PubMedID)
Available from: 2017-06-13 Created: 2017-06-13 Last updated: 2019-05-20Bibliographically approved
Sundström, E., Jensen, S. M., Diamant, U.-B. & Rydberg, A. (2017). Implantable cardioverter defibrillator treatment in long QT syndrome patients: a national study on adherence to international guidelines. Scandinavian Cardiovascular Journal, 51(2), 88-94
Open this publication in new window or tab >>Implantable cardioverter defibrillator treatment in long QT syndrome patients: a national study on adherence to international guidelines
2017 (English)In: Scandinavian Cardiovascular Journal, ISSN 1401-7431, E-ISSN 1651-2006, Vol. 51, no 2, p. 88-94Article in journal (Refereed) Published
Abstract [en]

Objectives. Implantable cardioverter defibrillator (ICD) treatment is effective among long QT syndrome (LQTS) patients at a high risk of sudden cardiac death. Previous studies show that the international guidelines are not always followed, and that risk stratification may be based on genotype rather than individual risk profile. We analysed data from the Swedish ICD & Pacemaker Registry and medical records to examine how international guidelines were followed with regards to phenotype and genotype. Methods and results. ICD treatment was used in 150 Swedish LQTS patients from 1989-2013. The annual number of implantations increased over the study period. A total of 109 patients were included in the analysis. Most patients (91%) were symptomatic before the implantation. Seventy percent of patients who received ICD treatment met the 2006 Class I or Class IIa recommendations for LQTS treatment. Thirty-one percent of the LQT3 patients received ICD treatment despite being asymptomatic. Among LQT1 patients, 45% received ICD treatment after syncope despite beta-blockers. Conclusions. Thirty percent of Swedish LQTS patients with ICD received the treatment without a strong indication based on international guidelines. LQT3 patients were over-represented among asymptomatic patients. Many LQT1 patients received ICD despite the known effect of beta-blockers in this group.

Keywords
Long QT syndrome, implantable cardioverter defibrillator, guidelines, beta-blocker treatment, orted cardiac arrest, syncope
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:umu:diva-133734 (URN)10.1080/14017431.2016.1270463 (DOI)000395166500005 ()27936942 (PubMedID)
Available from: 2017-05-08 Created: 2017-05-08 Last updated: 2019-05-20Bibliographically approved
Winbo, A., Stattin, E.-L., Westin, I. M., Norberg, A., Persson, J., Jensen, S. M. & Rydberg, A. (2017). Sex is a moderator of the association between NOS1AP sequence variants and QTc in two long QT syndrome founder populations: a pedigree-based measured genotype association analysis. BMC Medical Genetics, 18, Article ID 74.
Open this publication in new window or tab >>Sex is a moderator of the association between NOS1AP sequence variants and QTc in two long QT syndrome founder populations: a pedigree-based measured genotype association analysis
Show others...
2017 (English)In: BMC Medical Genetics, ISSN 1471-2350, E-ISSN 1471-2350, Vol. 18, article id 74Article in journal (Refereed) Published
Abstract [en]

Background: Sequence variants in the NOS1AP gene have repeatedly been reported to influence QTc, albeit with moderate effect sizes. In the long QT syndrome (LQTS), this may contribute to the substantial QTc variance seen among carriers of identical pathogenic sequence variants. Here we assess three non-coding NOS1APsequence variants, chosen for their previously reported strong association with QTc in normal and LQTS populations, for association with QTc in two Swedish LQT1 founder populations.

Methods: This study included 312 individuals (58% females) from two LQT1 founder populations, whereof 227 genotype positive segregating either Y111C (n = 148) or R518* (n = 79) pathogenic sequence variants in the KCNQ1 gene, and 85 genotype negatives. All were genotyped for NOS1AP sequence variants rs12143842, rs16847548 and rs4657139, and tested for association with QTc length (effect size presented as mean difference between derived and wildtype, in ms), using a pedigree-based measured genotype association analysis. Mean QTc was obtained by repeated manual measurement (preferably in lead II) by one observer using coded 50 mm/s standard 12-lead ECGs.

Results: A substantial variance in mean QTc was seen in genotype positives 476 ± 36 ms (Y111C 483 ± 34 ms; R518* 462 ± 34 ms) and genotype negatives 433 ± 24 ms. Female sex was significantly associated with QTc prolongation in all genotype groups (p < 0.001). In a multivariable analysis including the entire study population and adjusted for KCNQ1 genotype, sex and age, NOS1AP sequence variants rs12143842 and rs16847548 (but not rs4657139) were significantly associated with QT prolongation, +18 ms (p = 0.0007) and +17 ms (p = 0.006), respectively. Significant sex-interactions were detected for both sequent variants (interaction term r = 0.892, p < 0.001 and r = 0.944, p < 0.001, respectively). Notably, across the genotype groups, when stratified by sex neither rs12143842 nor rs16847548 were significantly associated with QTc in females (both p = 0.16) while in males, a prolongation of +19 ms and +8 ms (p = 0.002 and p = 0.02) was seen in multivariable analysis, explaining up to 23% of QTc variance in all males.

Conclusions: Sex was identified as a moderator of the association between NOS1AP sequence variants and QTc in two LQT1 founder populations. This finding may contribute to QTc sex differences and affect the usefulness of NOS1AP as a marker for clinical risk stratification in LQTS.

Keywords
Long QT syndrome, Sequence variants, Sex, Risk stratification, Modifier genes, QT prolongation, xsequence-variant interaction, Genotype-phenotype interactions, Founder populations
National Category
Medical Genetics
Identifiers
urn:nbn:se:umu:diva-138033 (URN)10.1186/s12881-017-0435-2 (DOI)000405695100001 ()
Available from: 2017-08-16 Created: 2017-08-16 Last updated: 2019-05-20Bibliographically approved
Kesek, M., Rydberg, A. & Jensen, S. M. (2016). Two Cases of LQT Syndrome with Malignant Syncope after Switch from Propranolol to Bisoprolol. Pacing and Clinical Electrophysiology, 39(3), 305-306
Open this publication in new window or tab >>Two Cases of LQT Syndrome with Malignant Syncope after Switch from Propranolol to Bisoprolol
2016 (English)In: Pacing and Clinical Electrophysiology, ISSN 0147-8389, E-ISSN 1540-8159, Vol. 39, no 3, p. 305-306Article in journal (Refereed) Published
Abstract [en]

Propranolol in slow-release form has been the first-line treatment in long QT (LQT) until it was withdrawn from the market. We describe two cases where a switch to bisoprolol resulted in worsening of arrhythmia control: A man with LQT2, asymptomatic on propranolol, experienced syncope after switching to bisoprolol 5 mg daily. He switched back to propranolol and has remained asymptomatic during subsequent 12 months. A man with classical Jervell Lange-Nielsen syndrome, previous gangliectomy, and ICD implantation, switched to bisoprolol 5 mg daily. Four months later he experienced a tachycardia storm. He switched back to propranolol and has remained free from arrhythmias during subsequent 12 months.

Keywords
long QT, pharmacology, beta-blocker therapy, bisoprolol, propranolol
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:umu:diva-118661 (URN)10.1111/pace.12783 (DOI)000372408200015 ()26548443 (PubMedID)
Available from: 2016-03-29 Created: 2016-03-29 Last updated: 2019-05-20Bibliographically approved
Walfridsson, H., Anfinsen, O.-G., Berggren, A., Frison, L., Jensen, S., Linhardt, G., . . . Carlsson, L. (2015). Is the acetylcholine-regulated inwardly rectifying potassium current a viable antiarrhythmic target?: Translational discrepancies of AZD2927 and A7071 in dogs and humans. Europace, 17(3), 473-482
Open this publication in new window or tab >>Is the acetylcholine-regulated inwardly rectifying potassium current a viable antiarrhythmic target?: Translational discrepancies of AZD2927 and A7071 in dogs and humans
Show others...
2015 (English)In: Europace, ISSN 1099-5129, E-ISSN 1532-2092, Vol. 17, no 3, p. 473-482Article in journal (Refereed) Published
Abstract [en]

Aims We aimed at examining the acetylcholine-dependent inward-rectifier current (I-KAch) as a target for the management of atrial fibrillation (AF). Methods and results The investigative agents AZD2927 and A7071 concentration-dependently blocked I-KAch in vitro with minimal off-target activity. In anaesthetized dogs (n -= 17) subjected to 8 weeks of rapid atrial pacing (RAP), the Left atrial effective refractory period (LAERP) was maximally increased by 50 +/- 7.4 and 50 +/- 4.8 ms following infusion of AZD2927 and A7071. Ventricular refractoriness and the QT interval were unaltered. During sustained AF, both drugs significantly reduced AF frequency and effectively restored sinus rhythm. AZD2927 successfully restored sinus rhythm at 10/10 conversion attempts and A7071 at 14/14 attempts, whereas saline converted 4/17 episodes only (P<0.001 vs. AZD2927 and A7071). In atrial flutter patients (n = 18) undergoing an invasive investigation, AZD2927 did not change LAERP, the paced QT interval, or ventricular refractoriness when compared with placebo. To address the discrepancy on LAERP by I-KAch blockade in man and dog and the hypothesis that atrial electrical remodelling is a prerequisite for &Act, blockade being efficient, six dogs were studied after 8 weeks of RAP followed by sinus rhythm for 4 weeks to reverse electrical remodelling. In these dogs, both AZD2927 and A7071 were as effective in increasing LAERP as in the dogs studied immediately after the 8-week RAP period. Conclusion Based on the present series of experiments, an important role of !1 in human atrial electrophysiology, as well as its potential as a viable target for effective management of AF, may be questioned.

Keywords
Antiarrhythmic agents, Arrhythmia, Electrophysiology, Ion channels, Remodelling
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:umu:diva-102229 (URN)10.1093/europace/euu192 (DOI)000351605000024 ()25082948 (PubMedID)
Available from: 2015-05-05 Created: 2015-04-22 Last updated: 2018-06-07Bibliographically approved
Bajraktari, G., Rönn, F., Ibrahimi, P., Jashari, F., Lindmark, K., Jensen, S. M. & Henein, M. Y. (2014). Combined electrical and global markers of dyssynchrony predict clinical response to Cardiac Resynchronization Therapy. Scandinavian Cardiovascular Journal, 48(5), 304-310
Open this publication in new window or tab >>Combined electrical and global markers of dyssynchrony predict clinical response to Cardiac Resynchronization Therapy
Show others...
2014 (English)In: Scandinavian Cardiovascular Journal, ISSN 1401-7431, E-ISSN 1651-2006, Vol. 48, no 5, p. 304-310Article in journal (Refereed) Published
Abstract [en]

AIM: To assess potential additional value of global left ventricular (LV) dyssynchrony markers in predicting cardiac resynchronization therapy (CRT) response in heart failure (HF) patients. METHODS: We included 103 HF patients (mean age 67 +/- 12 years, 83% male) who fulfilled the guidelines criteria for CRT treatment. All patients had undergone full clinical assessment, NT-proBNP and echocardiographic examination. Global LV dyssynchrony was assessed using total isovolumic time (t-IVT) and Tei index. On the basis of reduction in the NYHA class after CRT, patients were divided into responders and non-responders. RESULTS: Prolonged t-IVT [0.878 (range, 0.802-0.962), p = 0.005], long QRS duration [0.978 (range, 0.960-0.996), p = 0.02] and high tricuspid regurgitation pressure drop [1.047 (range, 1.001-1.096), p = 0.046] independently predicted response to CRT. A t-IVT >= 11.6 s/min was 67% sensitive and 62% specifi c (AUC 0.69, p = 0.001) in predicting CRT response. Respective values for a QRS >= 151 ms were 66% and 62% (AUC 0.65, p = 0.01). Combining the two variables had higher specifi city (88%) in predicting CRT response. In atrial fibrillation (AF) patients, only prolonged t-IVT [0.690 (range, 0.509 -0.937), p = 0.03] independently predicted CRT response. CONCLUSION: Combining prolonged t-IVT and the conventionally used broad QRS duration has a significantly higher specifi city in identifying patients likely to respond to CRT. Moreover, in AF patients, only prolonged t-IVT independently predicted CRT response.

Keywords
cardiac resynchronization therapy, echocardiography, heart failure, predictors, total isovolumic time
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:umu:diva-95273 (URN)10.3109/14017431.2014.950601 (DOI)000342346300009 ()
Available from: 2014-10-31 Created: 2014-10-27 Last updated: 2019-11-13Bibliographically approved
Bajraktari, G., Rönn, F., Ibrahimi, P., Jashari, F., Jensen, S. M. & Henein, M. Y. (2014). Combining electrical and global mechanical markers of LV dyssynchrony optimizes patient selection for cardiac resynchronization therapy.
Open this publication in new window or tab >>Combining electrical and global mechanical markers of LV dyssynchrony optimizes patient selection for cardiac resynchronization therapy
Show others...
2014 (English)Article in journal (Refereed) Submitted
Keywords
Cardiac resynchronization therapy, heart failure, predictors, echocardiography, total isovolumic time
National Category
Cardiac and Cardiovascular Systems
Research subject
Cardiology
Identifiers
urn:nbn:se:umu:diva-88473 (URN)
Available from: 2014-05-06 Created: 2014-05-06 Last updated: 2018-06-07Bibliographically approved
Organisations

Search in DiVA

Show all publications